Targeted & controlled bone healing
  • slidebg1
  • slidebg1
  • slidebg1
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

Kuros Biosciences are experts in the science of orthobiologics.

Our technology platforms aim to deliver improved patient outcomes through targeted and controlled bone healing.

We are poised to realise this aim through the launch of MagnetOs, based on our flagship surface science technology, and through the expansion of our portfolio by the continued clinical development of products based on our novel TG Hook technology.

Latest News
13 Dec 18
Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised


12 Dec 18
Kuros announces results of rights offering – capital increase will be implemented


Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Kuros has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action.

Kuros Biosciences are experts in the science of orthobiologics.

Our technology platforms aim to deliver improved patient outcomes through targeted and controlled bone healing.

We are poised to realise this aim through the launch of MagnetOs, based on our flagship surface science technology, and through the expansion of our portfolio by the continued clinical development of products based on our novel TG Hook technology.

Latest News
13 Dec 18
Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised


12 Dec 18
Kuros announces results of rights offering – capital increase will be implemented